164 related articles for article (PubMed ID: 27198854)
21. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates.
Maderna A; Leverett CA
Mol Pharm; 2015 Jun; 12(6):1798-812. PubMed ID: 25697404
[TBL] [Abstract][Full Text] [Related]
22. Aryl Sulfate is a Useful Motif for Conjugating and Releasing Phenolic Molecules: Sulfur Fluorine Exchange Click Chemistry Enables Discovery of Ortho-Hydroxy-Protected Aryl Sulfate Linker.
Park S; Kim SY; Cho J; Jung D; Seo D; Lee J; Lee S; Yun S; Lee H; Park O; Seo B; Woo SH; Park TK
Bioconjug Chem; 2019 Jul; 30(7):1957-1968. PubMed ID: 31251583
[TBL] [Abstract][Full Text] [Related]
23. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
[TBL] [Abstract][Full Text] [Related]
25. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
Akaiwa M; Dugal-Tessier J; Mendelsohn BA
Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
[TBL] [Abstract][Full Text] [Related]
26. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
[TBL] [Abstract][Full Text] [Related]
27. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
Edupuganti VVSR; Tyndall JDATDA; Gamble AB
Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
[TBL] [Abstract][Full Text] [Related]
28. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker.
Jeffrey SC; Nguyen MT; Moser RF; Meyer DL; Miyamoto JB; Senter PD
Bioorg Med Chem Lett; 2007 Apr; 17(8):2278-80. PubMed ID: 17293111
[TBL] [Abstract][Full Text] [Related]
29. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Kubizek F; Eggenreich B; Spadiut O
Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
[TBL] [Abstract][Full Text] [Related]
30. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.
Strop P; Liu SH; Dorywalska M; Delaria K; Dushin RG; Tran TT; Ho WH; Farias S; Casas MG; Abdiche Y; Zhou D; Chandrasekaran R; Samain C; Loo C; Rossi A; Rickert M; Krimm S; Wong T; Chin SM; Yu J; Dilley J; Chaparro-Riggers J; Filzen GF; O'Donnell CJ; Wang F; Myers JS; Pons J; Shelton DL; Rajpal A
Chem Biol; 2013 Feb; 20(2):161-7. PubMed ID: 23438745
[TBL] [Abstract][Full Text] [Related]
31. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
Joubert N; Denevault-Sabourin C; Bryden F; Viaud-Massuard MC
Eur J Med Chem; 2017 Dec; 142():393-415. PubMed ID: 28911823
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC
Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529
[TBL] [Abstract][Full Text] [Related]
33. Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.
Hamilton JZ; Pires TA; Mitchell JA; Cochran JH; Emmerton KK; Zaval M; Stone IJ; Anderson ME; Jin S; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
ChemMedChem; 2021 Apr; 16(7):1077-1081. PubMed ID: 33369163
[TBL] [Abstract][Full Text] [Related]
34. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.
Stagg NJ; Shen BQ; Brunstein F; Li C; Kamath AV; Zhong F; Schutten M; Fine BM
Regul Toxicol Pharmacol; 2016 Dec; 82():1-13. PubMed ID: 27773754
[TBL] [Abstract][Full Text] [Related]
35. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
36. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
[TBL] [Abstract][Full Text] [Related]
37. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
38. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
[TBL] [Abstract][Full Text] [Related]
39. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.
Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H
Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017
[TBL] [Abstract][Full Text] [Related]
40. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
